AstraZeneca PLC (AZN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth, particularly in oncology and biopharmaceuticals, with a 10% overall increase. Despite higher R&D expenses and a slight decline in operating margin, the focus on expanding product indications and late-stage pipeline projects is promising. The company's strategic investment in growth areas and the positive sales momentum in key segments suggest a favorable outlook, supporting a positive sentiment rating.
Key Financial Performance
Revenue $12.5 billion, up 10% year-over-year, driven by strong sales in oncology and biopharmaceuticals.
Oncology Sales $4.8 billion, increased by 12% year-over-year, attributed to the success of new product launches and expanded indications.
BioPharmaceuticals Sales $3.7 billion, grew by 8% year-over-year, supported by strong demand for respiratory and immunology products.
R&D Expenses $2.1 billion, up 15% year-over-year, reflecting increased investment in late-stage pipeline projects.
Operating Margin 30%, decreased by 2 percentage points year-over-year, due to higher R&D and marketing expenses.
Net Cash Flow $1.2 billion, declined by 5% year-over-year, impacted by increased capital expenditures and higher operating costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company's forward-looking statements involve inherent risks and uncertainties that could impact operations and financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Baker Rothschild
Bank PLC
Barclays Bank
Citigroup Inc
Co
Director Aradhana
Division EDT
Division Graham
Division Justin
Division Leuchten
Division Luisa
Division Mattias
Division Peter
Division Rajan
Division Sarita
Division Seamus
Division Simon
Division Uhde
EDT harbor
Executive Director
Glyn Parry
Gordon Barclays
Graham Glyn
Häggblom Handelsbanken
Jefferies LLC
Joris Silon
Justin Smith
LLC Research
Leuchten Jefferies
Luisa Hector
Marc Dunoyer
President BioPharmaceuticals
President Oncology
RD
Securities
Unit
AZN Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
